For women experiencing debilitating hot flushes and night sweats during menopause, a new non-hormonal treatment option is now available on the National Health Service (NHS) in England. The medication, known as Veoza (fezolinetant), offers a potential alternative for those unable to utilize hormone replacement therapy (HRT) or who prefer a different approach to managing their symptoms. This development marks a significant step forward in addressing a common and often disruptive phase of life for many women.
Menopause and the years leading up to it – known as perimenopause – can significantly impact a woman’s quality of life. Falling estrogen levels can trigger a cascade of symptoms, including hot flushes, night sweats, sleep disturbances, and emotional changes. Whereas HRT remains the first-line treatment for many, a substantial number of women cannot or choose not to use it, leaving them with limited options. Veoza aims to fill that gap, providing a new avenue for relief. Around 500,000 women in England could potentially benefit from this new treatment, according to estimates.
How Veoza Works
Veoza is a daily pill that works by blocking neurokinin 3 (NK3) receptors in the brain. These receptors play a role in regulating body temperature, and blocking them can reduce the frequency and severity of hot flushes and night sweats. The National Institute for Health and Care Excellence (NICE) – which provides guidance on healthcare practices in England – has recommended Veoza for treating moderate to severe symptoms of menopause, noting that the evidence demonstrates it can meaningfully reduce symptoms and represents good value for taxpayers. NICE director of medicines evaluation, Helen Knight, emphasized the importance of providing options for those unable to capture HRT, stating that options have “historically been limited.”
HRT Remains the First Line of Treatment
Despite the availability of Veoza, HRT remains the recommended first-line treatment for most women experiencing menopausal symptoms. NICE continues to highlight the established benefits and diverse forms of HRT – including tablets, patches, and gels – as reasons for its continued recommendation. Dr. Sue Mann, national clinical director in women’s health for NHS England, described the news as “incredibly welcome,” particularly for women who cannot or choose not to use HRT. She added that the drug could assist hundreds of thousands of women better manage their symptoms and feel more in control of their health.
Who is Veoza Not Suitable For?
It’s significant to note that Veoza is not appropriate for all women. NICE guidance specifies that This proves not recommended for individuals with breast cancer, other estrogen-dependent cancers, or liver disease. Women who have previously had breast cancer and completed treatment may be considered for Veoza on a case-by-case basis, depending on their individual circumstances. This highlights the importance of a thorough medical evaluation to determine the most suitable treatment option.
The approval of Veoza in England follows its initial approval in 2023. While the NICE recommendation currently applies to England, Wales and Northern Ireland often follow similar guidance. Scotland, however, has its own decision-making body for new drugs.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any health condition.
Looking ahead, the implementation of this new treatment option will be closely monitored to assess its impact on women’s health, and wellbeing. Further research may also explore the potential benefits of Veoza for other menopausal symptoms. We encourage readers to share their thoughts and experiences in the comments below.
